Feedback / Questions
Polivy (polatuzumab vedotin-piiq) - Roche
Lunsumio (mosunetuzumab-axgb) - Roche
Polivy + Lunsumio: Regulatory approval in US for 2L+ DLBCL in 2027
(Roche)
-
Oct 22, 2026 -
Q3 2026 Results
FDA approval
•
Diffuse Large B Cell Lymphoma • Hematological Malignancies • Oncology
https://assets.roche.com/f/176343/x/214d9ddfff/irp261022.pdf
Oct 22, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious